Back
Xeris Biopharma Holdings 10K Form
Buy
56
XERS
Xeris Biopharma Holdings
Last Price:
1.76
Seasonality Move:
-5.66%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
| 2020-08-10 | 10Q | XERS/Xeris Biopharma Holdings Quarterly |
| 2020-05-07 | 10Q | XERS/Xeris Biopharma Holdings Quarterly |
| 2020-03-12 | 10K | XERS/Xeris Biopharma Holdings Annual |
| 2019-11-07 | 10Q | XERS/Xeris Biopharma Holdings Quarterly |
| 2019-08-06 | 10Q | XERS/Xeris Biopharma Holdings Quarterly |
| 2019-05-09 | 10Q | XERS/Xeris Biopharma Holdings Quarterly |
Receive XERS News And Ratings
See the #1 stock for the next 7 days that we like better than XERS
XERS Financial Statistics
Sales & Book Value
| Annual Sales: | $163.91M |
|---|---|
| Cash Flow: | $7.34M |
| Price / Cash Flow: | 0 |
| Annual Sales: | $-0.05 |
| Price / Book: | 0 |
Profitability
| EPS (TTM): | -0.44000 |
|---|---|
| Net Income (TTM): | $-62.26M |
| Gross Margin: | $135.27M |
| Return on Equity: | -362.12% |
| Return on Assets: | -18.92% |
Xeris Biopharma Holdings Earnings Forecast
Key Xeris Biopharma Holdings Financial Ratios
- The Gross Profit Margin over the past 8 years for XERS is 82.52%.
- The Selling, General & Administrative Expenses for XERS have been equal to 89.13% of Gross Profit Margin.
- The Research & Development expenses have been 13.63% of Revenue.
- The Interest Expense is -42.74% of Operating Income.
- The Net Earning history of XERS is -37.98% of Total Revenues.
- Per Share Earnings over the last 8 years have been positive in 6 years.
Xeris Biopharma Holdings Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Pharmaceuticals |
| Sector: | Health Care |
| Current Symbol: | XERS |
| CUSIP: | 98422L |
| Website: | xerispharma.com |
Debt
| Debt-to-Equity Ratio: | -28.15 |
|---|---|
| Current Ratio: | 1.64 |
| Quick Ratio: | 1.17 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 0 |
XERS Technical Analysis vs Fundamental Analysis
Buy
56
Xeris Biopharma Holdings (XERS)
is a Buy
Is Xeris Biopharma Holdings a Buy or a Sell?
-
Xeris Biopharma Holdings stock is rated a Buy
The current Xeris Biopharma Holdings [XERS] share price is $1.75. The Score for XERS is 56, which is 12% above its historic median score of 50, and infers lower risk than normal.